Crovalimab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), DMC (Denmark) and NICE (England), among others, recommended or restricted crovalimab, while TLV (Sweden) did not recommend it.
Every record falls within a 1.2-year window, 19 Sep 2024 to 16 Dec 2025 — a compressed review cycle.
CIPM (Spain) changed its position: not recommended on 24 Apr 2025, recommended by 16 Jul 2025, after a resubmission.
No assessment is on file from HAS (France) and PBAC (Australia), each among the eight highest-volume agencies here.
The file is active: 11 of 11 records date from 2023 or later.
3 distinct indication wordings are recorded for crovalimab by the agencies that label one in English (AWMSG, NICE and SMC).
AWMSG (Wales) was first to assess crovalimab, on 19 Sep 2024; PHARMAC (New Zealand) did not open a file until 16 Dec 2025 — a moderate spread of 1.2 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 9 of 11 dated records fall in 2025 alone.
CIPM (Spain) is the only agency to have returned to crovalimab, recording 2 separate entries.
10 of the 18 agencies in this archive hold a record for crovalimab.
The full ledger for crovalimab reads 5 recommended, 2 not recommended, 2 restricted and 1 no benefit, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| TLV (Sweden) | 30 Sep 2025 | Piasky ingår inte i högkostnadsskyddet | rejection or exclusion | source |
| CIPM (Spain) | 16 Jul 2025 | Indicaciones terapéuticas autorizadas: Piasky en monoterapia está indicado para el tratamiento de pacientes adultos y pe… | financed by the SNS, on appeal · art. 92 a, c | source |
| ZIN (Netherlands) | 11 Jul 2025 | Advies - vergoed crovalimab (PiaSky®) voor de behandeling van paroxismale nachtelijke hemoglobinurie | reimbursed | source |
| AOTMIT (Poland) | 26 Jun 2025 | programu lekowego B.96 „Leczenie chorych z nocną napadową hemoglobinurią (ICD-10 D59.5) | recommended | source |
| G-BA (Germany) | 6 Mar 2025 | PiaSky — benefit assessment §35a | added benefit: not proven | source |
6 further decisions for crovalimab, across 6 agencies, are not shown here. They include the most recent record on file, 16 Dec 2025 from PHARMAC (New Zealand); its outcome is in the subscriber dataset. They link to 6 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 11 decisions for crovalimab from 10 agencies, 2024 to 2025. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.